NASDAQ:CYCCP
Cyclacel Pharmaceuticals Inc Stock News
$6.70
+0 (+0%)
At Close: May 17, 2024
Cyclacel Pharmaceuticals, Inc. (CYCC) Q1 2024 Earnings Call Transcript
08:08pm, Tuesday, 14'th May 2024
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC ) Q1 2024 Earnings Call Transcript May 14, 2024 4:30 PM ET Company Participants Grace Kim - IR Spiro Rombotis - President and CEO Brian Schwartz - CMO Paul
Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results
09:15am, Wednesday, 08'th May 2024
BERKELEY HEIGHTS, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative me
Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules
04:30pm, Thursday, 02'nd May 2024
BERKELEY HEIGHTS, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative me
Why Is Cyclacel Pharmaceuticals (CYCC) Stock Up 46% Today?
07:47am, Tuesday, 30'th Apr 2024
Cyclacel Pharmaceuticals (NASDAQ: CYCC ) stock is rocketing higher on Tuesday after the clinical-stage biopharmaceutical company withdrew a proposed public offering. A filing with the Securities and
Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
07:00am, Tuesday, 30'th Apr 2024
BERKELEY HEIGHTS, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative
- New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing development program in patients with solid tumors and lymphoma -
Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2023 Earnings Call Transcript
06:09pm, Tuesday, 19'th Mar 2024
Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2023 Earnings Call Transcript
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
04:05pm, Tuesday, 19'th Mar 2024
– On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2024 – – Expect to Report Final Data from Fadraciclib 065-101 Dose Escalation – – Oral Plogosertib Preclinical Data S
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
04:05pm, Wednesday, 13'th Mar 2024
BERKELEY HEIGHTS, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative
Data support ongoing development program of novel CDK2/9 inhibitor fadraciclib in patients with solid tumors and lymphoma Data support ongoing development program of novel CDK2/9 inhibitor fadraciclib
Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit
09:15am, Wednesday, 06'th Mar 2024
BERKELEY HEIGHTS, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative
Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference
09:15am, Tuesday, 20'th Feb 2024
BERKELEY HEIGHTS, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative m
Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer
09:15am, Tuesday, 30'th Jan 2024
BERKELEY HEIGHTS, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative m
Why Is Cyclacel Pharmaceuticals (CYCC) Stock Down 9% Today?
09:07am, Tuesday, 09'th Jan 2024
Cyclacel Pharmaceuticals (NASDAQ: CYCC ) stock is falling on Tuesday but it's not due to any negative news from the clinical-stage biopharmaceutical company. Instead, shares of CYCC stock are retreat
Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
09:15am, Monday, 08'th Jan 2024
BERKELEY HEIGHTS, N.J., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative m